TG THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TGTX in the last 7 days.
No SEC Form 4 filings for $TGTX in the last 30 days.
See all $TGTX insider activity →TG Therapeutics (TGTX) shares surged 85% YTD after a Betaville report suggested a potential takeover by a U.S. biopharma company. TGTX reported Q2 revenue of $227.7M for BRIUMVI, up 64% YoY, and raised its 2026 revenue target to $950M. Analysts maintain a 'Moderate Buy' rating with a $64 price target, implying 17% upside.
TG Therapeutics (TGTX) shares rose 11.9% as investors reassessed its growth outlook. The company raised 2026 revenue guidance for BRIUMVI and reported progress in its simplified dosing program. It also expects data from a Phase 3 trial of subcutaneous BRIUMVI by early 2027. Institutional investors have recently increased their positions in the stock.
US equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
Recent TGTX coverage spans earnings, market movers and financial news.
Takeover rumor drove a sharp price surge.
Guidance raise and trial data suggest stronger near-term sales and potential label expansion, supporting further upside.
Midday rally with no disclosed catalyst.
Short-term price rally driven by lower entry point and improved guidance.
Higher 2026 revenue guidance strengthens the near-term bull case for BRIUMVI commercial execution, but margin and payer-risk concerns remain.
AlphAI scores every news story that mentions TGTX with an AI model for sentiment and relevance, and aggregates insider trades from TG THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TG Therapeutics (TGTX) shares surged 85% YTD after a Betaville report suggested a potential takeover by a U.S. biopharma company. TGTX reported Q2 revenue of $227.7M for BRIUMVI, up 64% YoY, and raised its 2026 revenue target to $950M. Analysts maintain a 'Moderate Buy' rating with a $64 price target, implying 17% upside.
2 min readTG Therapeutics (TGTX) shares rose 11.9% as investors reassessed its growth outlook. The company raised 2026 revenue guidance for BRIUMVI and reported progress in its simplified dosing program. It also expects data from a Phase 3 trial of subcutaneous BRIUMVI by early 2027. Institutional investors have recently increased their positions in the stock.
2 min readUS equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
2 min readTG Therapeutics (TGTX) stock rose 5.9% to $53.55, recovering from a post-earnings selloff. Q2 revenue was $240M, up 70% YoY, and the company raised its 2026 revenue target to $950M. Despite an EPS miss, analysts remain bullish with price targets above current levels. The broader market's positive tone also supported the rally.
1 min readSimply Wall St reports TG Therapeutics (TGTX) posted Q2 2026 revenue of $240.34 million versus $141.15 million a year earlier, while net income fell to $7.78 million from $28.19 million. The company raised full-year 2026 total global revenue guidance to about $950 million, citing improved commercial trajectory.
4 min readTG Therapeutics (TGTX) reported Q2 2026 results with higher revenue and lower net income, and raised full-year revenue guidance to about $950 million, according to the company. The stock last traded at $47.94, framed by Simply Wall St as modestly undervalued versus a $51.71 fair value, largely tied to BRIUMVI ramp-up and market access.
4 min readTG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.
5 min readTG Therapeutics (TGTX) shares fell about 11% the day after earnings, as profit declined despite growth tied to BRIUMVI. The company reported Q2 2026 revenue of about $240.3M (up from $141.1M) and BRIUMVI revenue of about $228M, but net income fell to $7.8M and EPS to just over $0.05. Management cited manufacturing charges.
4 min readTG Therapeutics (TGTX.OB) reported Q2 results. Net income fell to $7.78 million, or $0.05 per share, from $28.19 million, or $0.17 per share, a year earlier. Revenue rose 70.3% to $240.33 million from $141.15 million. Full-year revenue guidance is $890 million to $905 million.
2 min readInvesting.com reports TG Therapeutics (TGTX) shares fell about 4.7% pre-open to $49.60 after its Q2 2026 results. The company said revenue was $240.3M versus ~$228.85M expected, and it raised FY2026 global revenue to about $950M and Briumvi U.S. net product revenue guidance to $890M-$905M. Despite beats, the market had priced in strong growth.
3 min read
